A Double-blinded, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of AION-301 Administered by Intravenous Infusion for the Treatment of Participants with Stage 3 Chronic Kidney Disease
Latest Information Update: 06 Feb 2025
Price :
$35 *
At a glance
- Drugs AION 301 (Primary)
- Indications Kidney disorders
- Focus Adverse reactions
- 03 Feb 2025 Planned primary completion date changed from 1 Jun 2026 to 1 Jan 2026.
- 03 Feb 2025 Status changed from not yet recruiting to recruiting.
- 12 Dec 2024 New trial record